Myriad Genetics
MYGN
186 hedge funds and large institutions have $2B invested in Myriad Genetics in 2024 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 72 increasing their positions, 63 reducing their positions, and 29 closing their positions.
1,852% more call options, than puts
Call options by funds: $6.32M | Put options by funds: $324K
15% more capital invested
Capital invested by funds: $1.74B → $2B (+$264M)
14% more repeat investments, than reductions
Existing positions increased: 72 | Existing positions reduced: 63
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 194 → 186 (-8)
5.97% less ownership
Funds ownership: 110.38% → 104.41% (-6%)
28% less first-time investments, than exits
New positions opened: 21 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$18.1M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$16.7M |
| 3 |
State Street
Boston,
Massachusetts
|
+$15.1M |
| 4 |
Millennium Management
New York
|
+$13.2M |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
+$8.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$11.5M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$7.33M |
| 3 |
GCM
Glenview Capital Management
New York
|
-$7.32M |
| 4 |
Goldman Sachs
New York
|
-$3.88M |
| 5 |
Envestnet Asset Management
Chicago,
Illinois
|
-$3.24M |
MYGN Hedge Fund Activity: Q1 2024 in Review
186 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Myriad Genetics (MYGN) for Q1 2024, worth a combined $2B — up 15% from $1.74B a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of MYGN and 21 opened new positions — a net loss of 8 holders — while 63 trimmed existing stakes and 72 added.
The largest buyer was Wellington Management Group, adding an estimated $18.1M. The largest seller was D.E. Shaw & Co, cutting an estimated $11.5M.
- 186 institutional investors held Myriad Genetics (MYGN) as of Q1 2024, down from 194 in Q4 2023.
- Funds reported $2B of Myriad Genetics stock for Q1 2024, up 15% quarter-over-quarter.
- 21 funds opened new Myriad Genetics positions in Q1 2024 and 29 closed out, a net change of -8 holders.
- The largest Myriad Genetics buyer in Q1 2024 was Wellington Management Group, an estimated $18.1M added.
- The largest Myriad Genetics seller in Q1 2024 was D.E. Shaw & Co, an estimated $11.5M sold.
Based on aggregated 13F filings for Q1 2024.